Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | CTSS | P25774 | 10/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938241 | 1.00 | CTSK (0.46) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL879326 | 1.00 | CTSK (0.46) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL1688920 | 0.92 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL3733285 | 0.92 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL3735030 | 0.92 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL14721778 | 0.89 | ACE (0.40) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL14721779 | 0.89 | ACE (0.40) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL15962292 | 0.89 | ACE (0.40) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL18397664 | 0.88 | CYP1A2 (0.57) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL13239937 | 0.88 | CTSK (0.43) | CTSKCTSSCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-9006271-B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006271-B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20140249188-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | NERRE THERAPEUTICS LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20140249188-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | NERRE THERAPEUTICS LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8822504-B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2014-09-02 | — | — | US | disclosed |
| US-8822504-B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2014-09-02 | — | — | US | disclosed |
| US-20130143931-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2013-06-06 | — | — | US | disclosed |
| US-8344005-B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoMethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2 as NK1 receptor antagonists | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-01-01 | — | — | US | disclosed |
| US-20080177072-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177072-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171879-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171879-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-7399766-B2 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399766-B2 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | CTSK 4380/4885CTSS 4492/4885CTSL 4544/4885 |
| US-20080171879-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | CTSK 3600/4885CTSS 3583/4885CTSL 3027/4885 |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | SCN2A, CACNA1B, HCN4 | CTSK 3600/4885CTSS 3583/4885CTSL 3027/4885 |
| US-20130143931-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | TACR1, BDKRB2, TACR2 | CTSK 933/4885CTSS 1316/4885CTSL 680/4885 |
| US-20080177072-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | CTSK 3600/4885CTSS 3583/4885CTSL 3027/4885 |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | KCNN2, KCNN1, KCNN3 | CTSK 1945/4885CTSS 1323/4885CTSL 468/4885 |
| US-20140249188-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | TACR1, BDKRB2, TACR2 | CTSK 933/4885CTSS 1316/4885CTSL 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.